{"id":4587,"date":"2023-09-06T09:14:51","date_gmt":"2023-09-06T09:14:51","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/orphan-drug-designation-odd-granted-to-vonafexor-for-alport-syndrome-by-both-the-european-medicines-agency-ema-and-the-u-s-food-and-drug-administration-fda\/"},"modified":"2023-09-06T14:14:42","modified_gmt":"2023-09-06T14:14:42","slug":"orphan-drug-designation-odd-granted-to-vonafexor-for-alport-syndrome-by-both-the-european-medicines-agency-ema-and-the-u-s-food-and-drug-administration-fda","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/orphan-drug-designation-odd-granted-to-vonafexor-for-alport-syndrome-by-both-the-european-medicines-agency-ema-and-the-u-s-food-and-drug-administration-fda\/","title":{"rendered":"Vonafexor est d\u00e9sign\u00e9 m\u00e9dicament orphelin (Orphan Drug Designation) pour le traitement du syndrome d&#8217;Alport par l&#8217;EMA et la FDA"},"content":{"rendered":"<p>Â鶹Æƽâ°æ annonce que la &#8220;d\u00e9signation m\u00e9dicament orphelin&#8221; (Orphan Drug Designation) a \u00e9t\u00e9 attribu\u00e9e \u00e0 Vonafexor pour le traitement du syndrome d&#8217;Alport par l&#8217;Agence europ\u00e9enne des m\u00e9dicaments (European Medicines Agency, EMA) et l\u2019agence f\u00e9d\u00e9rale am\u00e9ricaine des produits alimentaires et m\u00e9dicamenteux des \u00c9tats-Unis (Food and Drug Administration, FDA).<\/p>\n<p>Le syndrome d&#8217;Alport est une maladie g\u00e9n\u00e9tique rare affectant 1 naissance sur 5 000 \u00e0 10 000. Elle se caract\u00e9rise par une perte progressive de la fonction r\u00e9nale et peut entra\u00eener une surdit\u00e9 et une atteinte oculaire.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Â鶹Æƽâ°æ annonce que la &#8220;d\u00e9signation m\u00e9dicament orphelin&#8221; (Orphan Drug Designation) a \u00e9t\u00e9 attribu\u00e9e \u00e0 Vonafexor pour le traitement du syndrome d&#8217;Alport par l&#8217;Agence europ\u00e9enne des m\u00e9dicaments (European Medicines Agency, EMA) et l\u2019agence f\u00e9d\u00e9rale am\u00e9ricaine des produits alimentaires et m\u00e9dicamenteux des \u00c9tats-Unis (Food and Drug Administration, FDA).<\/p>\n<p>Le syndrome d&#8217;Alport est une maladie g\u00e9n\u00e9tique rare affectant 1 naissance sur 5 000 \u00e0 10 000. Elle se caract\u00e9rise par une perte progressive de la fonction r\u00e9nale et peut entra\u00eener une surdit\u00e9 et une atteinte oculaire.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/orphan-drug-designation-odd-granted-to-vonafexor-for-alport-syndrome-by-both-the-european-medicines-agency-ema-and-the-u-s-food-and-drug-administration-fda\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[21],"tags":[],"class_list":["post-4587","post","type-post","status-publish","format-standard","hentry","category-latest-news-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/latest-news-fr\/\" rel=\"category tag\">Br\u00e8ves<\/a>","rttpg_excerpt":"Â鶹Æƽâ°æ annonce que la &#8220;d\u00e9signation m\u00e9dicament orphelin&#8221; (Orphan Drug Designation) a \u00e9t\u00e9 attribu\u00e9e \u00e0 Vonafexor pour le traitement du syndrome d&#8217;Alport par l&#8217;Agence europ\u00e9enne des m\u00e9dicaments (European Medicines Agency, EMA) et l\u2019agence f\u00e9d\u00e9rale am\u00e9ricaine des produits alimentaires et m\u00e9dicamenteux des \u00c9tats-Unis (Food and Drug Administration, FDA). Le syndrome d&#8217;Alport est une maladie g\u00e9n\u00e9tique rare&hellip;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/4587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=4587"}],"version-history":[{"count":11,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/4587\/revisions"}],"predecessor-version":[{"id":4627,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/4587\/revisions\/4627"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=4587"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=4587"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=4587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}